An Act relative to patient access to biomarker testing to provide appropriate therapy

This bill requires health insurance plans covering commonwealth employees (under group insurance) and Medicaid enrollees to cover biomarker testing - tests analyzing tissue or blood to identify biological markers for guiding treatment - when supported by medical evidence like FDA approvals, clinical guidelines, or CMS determinations. Insurers must approve or deny prior authorization requests within 72 hours (24 hours in emergencies), with automatic approval if no response is given. The bill also mandates coverage without unnecessary disruptions, such as multiple biopsies, to ensure continuous patient care.